Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial

Children's Oncology Group10 enrolled

Overview

RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies DNA samples from patients with Down syndrome and acute myeloid leukemia treated on COG-AAML0431 clinical trial.

OBJECTIVES: * To identify new genetic abnormalities associated with acute myeloid leukemia (AML) in patients with Down syndrome through whole-genome sequencing. OUTLINE: This is a multicenter study. Extracted DNA and RNA from cryopreserved specimens are analyzed for genomic sequencing, gene mutation, and microarray analysis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia

Interventions

gene mappingGENETIC

microarray analysisGENETIC

mutation analysisGENETIC

nucleic acid sequencingGENETIC

Eligibility

Sex: ALLMax age: 3 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Down syndrome children diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) * Clinical samples from patients enrolled on the Children's Oncology Group (COG) AAML0431 phase III clinical trial, and from the Children's Hospital of Michigan Cell Bank * Diagnostic blast samples and matched remission samples PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Outcomes

Primary Outcomes

Identification of unique mutations through whole-genome sequencing

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.